Evoke Pharma EBIT Margin 2012-2023 | EVOK
Current and historical EBIT (Earnings Before Interest & Taxes) margin for Evoke Pharma (EVOK) over the last 10 years. The current EBIT profit margin for Evoke Pharma as of December 31, 2023 is .
Evoke Pharma EBIT Margin Historical Data |
Date |
TTM Revenue |
TTM EBIT |
EBIT Margin |
2023-12-31 |
$0.01B |
$-0.01B |
-133.33% |
2023-09-30 |
$0.01B |
$-0.01B |
-160.00% |
2023-06-30 |
$0.00B |
$-0.01B |
-200.00% |
2023-03-31 |
$0.00B |
$-0.01B |
-266.67% |
2022-12-31 |
$0.00B |
$-0.01B |
-400.00% |
2022-09-30 |
$0.00B |
$-0.01B |
-800.00% |
2022-06-30 |
$0.00B |
$-0.01B |
-800.00% |
2022-03-31 |
$0.00B |
$-0.01B |
-800.00% |
2021-12-31 |
$0.00B |
$-0.01B |
-900.00% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.004B |
$0.005B |
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|